Outlook Therapeutics Reports $23.1 Million Net Loss and Negative Revenue for December 2025 Quarter

Outlook Therapeutics, Inc. reported a net loss of $23.1 million for the three months ending December 31, 2025, a significant decline from a net income of $17.4 million during the same period in 2024. The company's revenues for the quarter were negative $1.2 million, attributed primarily to a $1.1 million increase in the returns reserve related to lower-than-expected product sell-through from its UK distributor. This marks a stark contrast to the previous year when the company reported no revenue. The gross profit for the quarter was also negative, at $(1.2 million), reflecting the challenges in product sales and the impact of administrative fees.

In terms of operational expenses, Outlook Therapeutics saw a decrease in research and development costs, which fell to $3.6 million from $9.7 million in the prior year. This reduction was largely due to decreased spending on the development of its lead product, ONS-5010/LYTENAVA, as the company shifted focus following the completion of patient enrollment in the NORSE EIGHT clinical trial. Selling, general, and administrative expenses also decreased to $8.6 million from $11.9 million, primarily due to lower compensation costs following workforce reductions and a decrease in professional fees.

The company’s financial position as of December 31, 2025, showed total assets of $18.2 million, down from $18.6 million at the end of the previous fiscal year. Current liabilities increased to $49.1 million, up from $45.8 million, largely due to the current portion of an unsecured convertible promissory note. The accumulated deficit grew to $628.8 million, reflecting ongoing operational losses. Outlook Therapeutics has indicated that it will require additional financing to support its operations and product commercialization efforts, particularly for ONS-5010/LYTENAVA, which is currently under review by the FDA.

Strategically, the company has made significant progress with its product, LYTENAVA, which received marketing authorization in the European Union and the United Kingdom in 2024. The product was launched commercially in Germany and the UK in June 2025. However, the company faces challenges in the U.S. market, where it is working to address regulatory concerns raised by the FDA regarding its Biologics License Application. Outlook Therapeutics is currently evaluating various funding strategies, including potential licensing agreements and additional equity or debt offerings, to ensure it can continue its operations and support the commercialization of its products.

Looking ahead, Outlook Therapeutics has expressed substantial doubt about its ability to continue as a going concern without securing additional funding. The company is actively seeking to navigate the regulatory landscape for ONS-5010/LYTENAVA while managing its financial obligations, including a recent Major Trigger Event related to its convertible promissory note. The management's focus remains on obtaining the necessary resources to advance its product pipeline and achieve market acceptance.